Jemperli (dostarlimab)

pCPA File Number: 22696

Negotiation Status:

Active Negotiation

Indication(s):

Primary advanced or recurrent mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) endometrial cancer in adult patients who are candidates for systemic therapy (in combination with carboplatin and paclitaxel)

Sponsor/Manufacturer:

GlaxoSmithKline Inc.

CDA-AMC Project Number:

PC0325-000

pCPA Engagement Letter Issued:

2024-07-11

Negotiation Process Concluded:

Not Applicable